As the Society of Toxicology (SOT) Annual Meeting approaches, biopharmaceutical companies have a prime opportunity to engage with industry leaders and explore innovative solutions to advance drug development initiatives. This year, the team at Scantox extends a warm...
News archive
Scantox acquires QPS Austria’s Neuropharmacology Division
30th November 2023 -- Today Scantox, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria GmbH (“QPS Neuro” or “the Company”) ultimately owned by QPS Holdings LLC. QPS Neuro is a leading drug discovery Contract...
Scantox continues its growth journey with the acquisition of Solural Pharma
Scantox A/S (“Scantox”) announces the acquisition of Solural Pharma (“Solural”) in Denmark. Scantox is the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo. Solural has strong...
Scantox appoints Morten Fjordholt as Sr. Business Development Director
November 8th – Scantox Group, a leading provider of nonclinical services in Europe, has named Morten Fjordholt as Sr. Business Development Director with the overall responsibility of growing sales within toxicology and lab services and fostering positive relationships...
Scantox acquires Q&Q – strengthening its offering within bioanalytical services
31 August 2023 -- Scantox A/S (“Scantox” or the “Company”), the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo, is pleased to announce the acquisition of Q&Q Labs AB located...
Scantox appoints Andy Brown as Group Chief Commercial Officer
July 7th – Scantox Group, a leading provider of nonclinical services in Europe, has named Andy Brown as Group Chief Commercial Officer with the overall responsibility of growing sales within toxicology, discovery and lab services and fostering positive relationships...
Exclusive genOway distributors in the Nordics
Scantox is pleased to announce that we are exclusive distributors of advanced preclinical models, including the BRGSF-HIS and advanced humanized immune checkpoint models from genOway in Demark, Sweden, Norway and Finland. The genOway BRGSF-HIS mouse possesses the most...
Scantox Certified as 2023 Great Place to Work
Scantox is proud to be certified by Great Place to Work™. This prestigious award is based entirely on what current employees say about their experience of working at Scantox. It takes an entire team of dedicated individuals to achieve what we do at Scantox. Each...
Scantox Wins ’Company of the Year 2022’ Award
At the annual New Years Celebration arranged by Connect Køge, Scantox was announced as this year’s winner of the ’Company of the Year 2022’ award. Two other nominees were in the race for the award. ”Within their specific line of business, the winning company is a...
Danish Award Nomination
Scantox Group is one of this year's proud nominees to the title 'Company of the Year 2022' in the Køge area in Denmark where our HQ is located. Three companies are nominated for all having done an outstanding effort to support local initiatives in the past year. The...
Humanized Minipigs
With the recently published article in the scientific publication Nature Biomedical Engineering, “A humanized minipig model for the toxicological testing of therapeutic recombinant antibodies”, the new Humanized Minipig is now commercially available, and Scantox will...
Scantox acquires Timeline Bioresearch and Adlego Biomedical
Scantox acquires Timeline Bioresearch and Adlego Biomedical – strengthening its position as the leading Nordic provider of pre-clinical research services. Scantox A/S (“Scantox” or the “Company”), the leading Nordic GLP-compliant...